Ishikawa Tomoe, Yasui Masato
Department of Pharmacology, Keio University School of Medicine.
Brain Nerve. 2021 Sep;73(9):983-989. doi: 10.11477/mf.1416201875.
Cerebral edema is a major contributor to the mortality associated with ischemic stroke and traumatic brain injuries; however, limited therapeutic strategies are available for cerebral edema. Aquaporin-4 (AQP4), the main water channel in the brain plays a key role in water homeostasis and edema formation in the central nervous system. Therefore, regulation of AQP4 function or expression is considered a possible target for treatment of edema. Despite extensive research over several decades, AQP4 inhibitors have not been approved for the treatment of edema in humans. Further studies are warranted to gain a deeper understanding of the exact properties and functions of AQP4, to facilitate the development of newer therapeutic approaches for cerebral edema.
脑水肿是缺血性中风和创伤性脑损伤相关死亡率的主要促成因素；然而，针对脑水肿的治疗策略有限。水通道蛋白4（AQP4）是大脑中的主要水通道，在中枢神经系统的水平衡和水肿形成中起关键作用。因此，调节AQP4的功能或表达被认为是治疗水肿的一个可能靶点。尽管经过几十年的广泛研究，AQP4抑制剂尚未被批准用于治疗人类水肿。有必要进行进一步研究，以更深入地了解AQP4的确切特性和功能，促进开发针对脑水肿的更新治疗方法。
